U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07902804) titled 'A Study of IBI3043 Treatment in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors' on Oct. 22.
Brief Summary: This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3043 in participants with unresectable,locally advanced, or metastatic solid tumors. The study will be conducted in two phases: Phase 1 dose escalation and Phase 2 dose expansion. Safety will be monitored by the Safety Review Committee (SRC).
Study Start Date: Nov. 16
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: IBI3043
IBI3043 is an investigational drug administered as Q2W or Q3W ac...